Alpharma Asks Appeals Court To Remove Stay On Neurontin Capsule Launch

Law360, New York (September 13, 2004, 12:00 AM EDT) -- Generics maker Alpharma Inc. has asked an appeals court to lift its order to stay the U.S. Food and Drug Administration’s final approval of the company’s generic version of Pfizer's epilepsy treatment Neurontin.

If the stay is lifted, Alpharma plans to commence commercial sales of gabapentin capsules, the generic name of Neurontin, the company said in a statement.

Alpharma’s plans to start the commercial sales of gabapentin capsules are not contingent on the conclusion of the ongoing patent infringement case with Pfizer, according to the generics...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.